DNMT1 and myelodysplastic syndrome: DNMT inhibitors (i.e., 5-azacytidine and 5-aza-2′-deoxycytidine) were recently approved by the Food and Drug Administration (FDA) for the treatment of myelodysplastic syndromes and acute myeloid leukemia, respectively, based on their capacity to target DNA methylation induced by metabolic change.